IBM-1 description of the fission products 108,110,112^{108,110,112}Ru

IBM-1} calculations for the fission products $^{108,110,112}$Ru have been carried out. The even-even isotopes of Ru can be described as transitional nuclei situated between the U(5) (spherical vibrator) and SO(6) ($\gamma$-unstable rotor) symmetries of the Interacting Boson Model. At first, a Hamiltonian with only one- and two-body terms has been used. Excitation energies and $B$(E2) ratios of gamma transitions have been calculated. A satisfactory agreement has been obtained, with the exception of the odd-even staggering in the quasi-$\gamma$ bands of $^{110,112}$Ru. The observed pattern is rather similar to the one for a rigid triaxial rotor. A calculation based on a Hamiltonian with three-body terms was able to remove this discrepancy. The relation between the IBM and the triaxial rotor model was also examined.Comment: 22 pages, 8 figure

Decoherence control in microwave cavities

We present a scheme able to protect the quantum states of a cavity mode against the decohering effects of photon loss. The scheme preserves quantum states with a definite parity, and improves previous proposals for decoherence control in cavities. It is implemented by sending single atoms, one by one, through the cavity. The atomic state gets first correlated to the photon number parity. The wrong parity results in an atom in the upper state. The atom in this state is then used to inject a photon in the mode via adiabatic transfer, correcting the field parity. By solving numerically the exact master equation of the system, we show that the protection of simple quantum states could be experimentally demonstrated using presently available experimental apparatus.Comment: 13 pages, RevTeX, 8 figure

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362